CD274 and non-small cell lung carcinoma: However, for most of the included years, PD-(L)1 inhibitor monotherapy was recommended in Sweden in advanced NSCLC with high PD-L1 expression, and it is unlikely that a significant part of the PS0-1 patients with high PD-L1 expression in our study was planned for combination therapy but were unable to receive chemotherapy.